期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PPARs在长链脂肪酸调控能量代谢中的作用 被引量：7

PPARs Mediate the Regulation of Energy Metabolism By Long-Chain Fatty Acids
下载PDF
导出
摘要 过氧化物酶体增殖物激活受体α(PPARα)主要在肝脏中表达,饥饿时能诱导β-氧化与生酮作用相关基因和成纤维化生长因子21(FGF21)表达,这在肝脏的饥饿代谢适应中起重要作用。饥饿与耐力训练时,骨骼肌中,过氧化物酶体增殖物激活受体δ(PPARδ)能诱导长链脂肪酸(LCFAs)氧化基因、叉头转录因子(FOXO1)及PPARδ共激活物α1(PGC1α)表达,其中,FOXO1和PGC1α能调控糖代谢与线粒体生物发生。脂肪细胞中,PPARγ能介导LCFAs调控能量代谢,活化的PPARγ能诱导与LCFAs转化为甘油三酯形式储存相关的基因表达。脂联素,PPARγ的另一靶基因,能维持脂肪细胞的胰岛素敏感性。本文就PPARs在LCFAs调控能量代谢中的作用做一综述。 PPAR-alpha expressed primarily in liver is essential for metabolic adaptation to starvation by inducing genes for beta-oxidation and ketogenesis to increase the utility of LCFAs and fibroblast growth factor 21. PPAR-delta induces genes for LCFA oxidation during fasting and endurance exercise in skeletal muscle. PPAR-deha also regulates glucose metabolism and mitochondrial biogenesis by inducing FOXO1 and PGCl-alpha. PPAR-gamma can induces the pathways to store LCFAs as triglycerides in adipocytes . Adiponectin, another important target of PPAR-gamma may maintain insulin sensitivity between adipo- cytes. The present review summarize that PPARs mediate the regulation of energy metabolism by long- chain fatty acids.
作者 姚艳 王宗保 唐朝克
机构地区 南华大学心血管病研究所 南华大学药学与生物科学学院
出处 《生理科学进展》 CAS CSCD 北大核心 2016年第1期1-6,共6页 Progress in Physiological Sciences
基金 国家自然科学基金(81370377)资助课题
关键词 过氧化物酶体增殖物激活受体 长链脂肪酸 能量代谢 脂联素 PPARs LCFAs energy metabolism adiponectin
分类号 R363 [医药卫生—病理学]
  • 相关文献

参考文献29

  • 1Akbar H, Schmitt E, Ballou MA, et al. Dietary lipid during late-pregnancy and early-lactation to manipulate metabolic and inflammatory gene network expression in dairy cattle liver with a focus on PPARs. Gene Regul Syst Bio,2013 , 7 : 103 -123.
  • 2Gonzalez JM, Fisher SZ. Structural analysis of ibuprofen binding to human adipocyte fatty-acid binding protein ( F ABP4). Acta Crystallogr F Struct Biol Commun, 2015 , 71 : 163 -170.
  • 3Yu S, Reddy JK. Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et biophysica acta,2007, 1771 : 936 -951.
  • 4Cheon Y, Nara TY, Band MR, et al. Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PP ARalpha in nonproliferating species. Am J Physiol Regul Integr Comp Physiol,2005, 288 : R1525 - R1535.
  • 5Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acylCoA dehydrogenation deficiency. Brain, 2007 , 130 : 2045 - 2054.
  • 6Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab, 2007, 5 : 415 - 425.
  • 7Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation ,2015 ,13 : 1861 -1871.
  • 8Zhao TJ, Liang G, Li RL, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci USA, 2010, 107 : 7467 -7472.
  • 9Kim YD, Li T, Ahn SW, et al. Orphan nuclear receptor small heterodimer partner negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of signal transducer and activator of transcription 5 (STAT5) transactivation. J BioI Chern, 2012, 287 : 37098 - 37108.
  • 10张扬,朱昆.贝特类调血脂前药与类似物的研究进展[J].吉林化工学院学报,2014,31(3):38-42. 被引量：1

二级参考文献34

  • 1杨宝峰.药理学[M].8版.北京:人民卫生出版社,2013:1-484.
  • 2Fruchart,J.C.; Sacks,F.M.; Hermans,M.P.,et al.The residual risk reduction initiative:a call to action to reduce residual vascular risk in dyslipidaemic patient[J].Diab.Vasc.Dis.Res.,2008,5(4):319-335.
  • 3Kubo,S.H.;Cody,R.J.Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors.A review[J].Clin.Pharmacokinet.1985,10(5):377-391.
  • 4Mizuno,N.; Niwa,T.; Yotsumoto,Y.,et al.Impact of drug transporter studies on drug discovery and development[J].Pharmacol.Rev.2003,55 (3):425-461.
  • 5Baudy,R.B.; Butera,J.A.; Abou-Gharbia,M.A.,et al.Prodrugs of perzinfotel with improved oral bioavailability[J].J.Med.Chem.2009,52 (3):771-778.
  • 6Xie,Q.; Wang,X.; Jiang,Z.; Qiu,Z.Design,synthesis,and bioavailability evaluation of coumarin-based prodrug of meptazinol[J].Bioorg.Med.Chem.Lett.2005,15 (22):4953-4956.
  • 7Kahns,A.H.; Moss,J.; Bundgaard,H.Inproved oral bioavailability of salicylamide in rabbits by a 1,3-benzoxazine-2,4-dione prodrug[J].Int.J.Pharm.1992,78 (1-3),199-202.
  • 8Zhang,Y.; Yang,Y.; Zhao S.,et al.Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake[J].Molecules.2013,18,14920-14934.
  • 9Horn,A.S.;Kelly,P.;Westerink,B.H.,et al.A prodrug of ADTN:Selectivity of dopaminergic action and brain levels of ADTN[J].Eur.J.Pharmacol.1979,60(1),95-99.
  • 10Bandgar,B.P.; Sarangdhar,R.J.; Viswakarma,S.,et al.Synthesis and biological evaluation of orally active prodrugs of indomethacin[J].J.Med.Chem.2011,54 (5):1191-1201.

同被引文献70

引证文献7

二级引证文献24

生理科学进展
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部